ALLO

Allogene Therapeutics, Inc.

ALLO · CIK 1737287 · Annual (10-K) · Last 7 years

Financial Trends

Revenue$0M
20182024
Net Income−$258M
20182024
Operating CF−$200M
20182024
Free Cash Flow−$201M
20182024

Income Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Revenue$0.0B$0.0B$0.0B$0.0B———
Cost of Revenue———————
Gross Profit———————
R&D Expense$0.2B$0.2B$0.3B$0.2B$0.2B$0.1B$0.2B
SG&A Expense———————
Operating Income$-0.3B$-0.3B$-0.3B$-0.3B$-0.3B$-0.1B$0.0B
Net Income$-0.3B$-0.3B$-0.3B$-0.3B$-0.3B$-0.1B$-0.0B
EPS (Basic)$-1.32$-2.09$-2.32$-1.89———
EPS (Diluted)$-1.32$-2.09$-2.32$-1.89———

Balance Sheet

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Total Assets$0.5B$0.6B$0.8B$1.0B$1.2B$0.7B$0.8B
Current Assets$0.3B$0.5B$0.5B$0.5B$0.8B$0.5B$0.5B
Cash & Equivalents$0.1B$0.1B$0.1B$0.2B$0.2B$0.2B$0.1B
Total Liabilities$0.1B$0.1B$0.2B$0.1B$0.1B$0.1B$0.1B
Current Liabilities$0.0B$0.0B$0.1B$0.0B$0.1B$0.0B$0.0B
Stockholders' Equity$0.4B$0.5B$0.7B$0.9B$1.1B$0.6B$0.7B

Cash Flow Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Operating Cash Flow$-0.2B$-0.2B$-0.2B$-0.2B$-0.1B$-0.1B$-0.0B
Investing Cash Flow$0.1B$0.2B$0.1B$0.2B$-0.5B$0.2B$-0.6B
Capital Expenditures$0.0B$0.0B$0.0B$0.0B$0.1B$0.1B$0.0B
Financing Cash Flow$0.1B$0.1B$0.0B$0.0B$0.6B$0.1B$0.8B
← Companies